Detalhe da pesquisa
1.
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Breast Cancer Res
; 26(1): 36, 2024 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38439079
2.
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
Prostate
; 84(2): 177-184, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37846041
3.
Proceedings of the 2023 Santa Fe Bone Symposium: Progress and Controversies in the Management of Patients with Skeletal Diseases.
J Clin Densitom
; 26(4): 101432, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37944445
4.
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
Cancer
; 126(20): 4532-4544, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32767682
5.
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Breast Cancer Res Treat
; 184(1): 53-62, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32803633
6.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.
Endocr Pract
; 26(Suppl 1): 1-46, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32427503
7.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY.
Endocr Pract
; 26(5): 564-570, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32427525
8.
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol
; 154(2): 294-301, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31174889
9.
Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
Br J Clin Pharmacol
; 85(6): 1125-1135, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30536446
10.
Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?
Clin Diabetes
; 37(4): 316-337, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31660005
11.
Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy.
Oncologist
; 22(4): 438-444, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28275116
12.
NCCN bone health task force: key recommendations.
J Natl Compr Canc Netw
; 12(5 Suppl): 813-6, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24853223
13.
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
JCO Oncol Pract
; 20(3): 393-400, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190588
14.
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
NPJ Breast Cancer
; 10(1): 12, 2024 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38297009
15.
NCCN Task Force Report: Bone Health In Cancer Care.
J Natl Compr Canc Netw
; 11 Suppl 3: S1-50; quiz S51, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23997241
16.
Maintaining Bone Health During Hormonal Therapy for Prostate Cancer.
Ann Intern Med
; 167(5): 357-358, 2017 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28785765
17.
Refractory hypercalcemia of malignancy: a problem with many potential roots.
Front Endocrinol (Lausanne)
; 14: 1088984, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37265703
18.
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
; 26(1): 126-132, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35798857
19.
Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
J Oral Maxillofac Surg
; 70(12): 2768-75, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22330331
20.
Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia.
Integr Cancer Ther
; 21: 15347354211073163, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35075945